U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H14F3N3O2S
Molecular Weight 369.3632
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LANSOPRAZOLE

SMILES

Cc1c(CS(=O)c2[nH]c3ccccc3n2)nccc1OCC(F)(F)F

InChI

InChIKey=MJIHNNLFOKEZEW-UHFFFAOYSA-N
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

HIDE SMILES / InChI

Molecular Formula C16H14F3N3O2S
Molecular Weight 369.3632
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Dexlansoprazole (trade names Kapidex, Dexilant) is a proton pump inhibitor (PPI) that is marketed by Takeda Pharmaceuticals for the treatment of erosive esophagitis and gastro-oesophageal reflux disease. Dexlansoprazole is used to heal and maintain healing of erosive esophagitis and to treat heartburn associated with gastroesophageal reflux disease (GERD). It lasts longer than lansoprazole, to which it is chemically related, and needs to be taken less often. Dexlansoprazole is supplied for oral administration as a dual delayed-release formulation in capsules and orally disintegrating tablets. The capsules and tablets contain dexlansoprazole in a mixture of two types of enteric-coated granules with different pH-dependent dissolution profiles. The most significant adverse reactions (≥2%) reported in clinical trials were diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DEXILANT

Approved Use

DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Launch Date

1233273600000
Curative
DEXILANT

Approved Use

DEXILANT is a proton pump inhibitor (PPI) indicated for: •Healing of all grades of erosive esophagitis (EE). (1.1) •Maintaining healing of EE and relief of heartburn. (1.2) •Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). (1.3) 1.1 Healing of Erosive Esophagitis DEXILANT is indicated for healing of all grades of erosive esophagitis (EE) for up to eight weeks. 1.2 Maintenance of Healed Erosive Esophagitis DEXILANT is indicated to maintain healing of EE and relief of heartburn for up to six months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease DEXILANT is indicated for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Launch Date

1233273600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1136 ng/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
691 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
16.1 (ng/mL)/mg
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
33.5 (ng/mL)/mg
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
37.3 (ng/mL)/mg
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
1005 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
559 ng/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
964 ng/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
658 ng/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
1397 ng/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
143.2 (ng*h/mL)/mg
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
55.5 (ng*h/mL)/mg
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
87.6 (ng*h/mL)/mg
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2149 ng*h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2628 ng*h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3330 ng*h/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
128 (ng*h/mL)/mg
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
62 (ng*h/mL)/mg
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
96 (ng*h/mL)/mg
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
1914 ng*h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
2892 ng*h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3747 ng*h/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Children
sex:
food status:
3275 ng × h/mL
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
6529 ng × h/mL
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.59 h
60 mg 1 times / day multiple, oral
dose: 60 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
1.66 h
30 mg 1 times / day multiple, oral
dose: 30 mg
route of administration: oral
experiment type: multiple
co-administered:
DEXLANSOPRAZOLE plasma
Homo sapiens
population: unhealthy
age: Adolescents
sex:
food status:
Doses

Doses

DosePopulationAdverse events​
30 mg 2 times / day multiple, intravenous
Dose: 30 mg, 2 times / day
Route: intravenous
Route: multiple
Dose: 30 mg, 2 times / day
Sources:
healthy, 18-29 years
Health Status: healthy
Age Group: 18-29 years
Sex: M+F
Sources:
90 mg single, intravenous
Dose: 90 mg
Route: intravenous
Route: single
Dose: 90 mg
Sources:
healthy, 18-29 years
Health Status: healthy
Age Group: 18-29 years
Sex: M+F
Sources:
300 mg single, oral
Highest studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
healthy, 35 years (range: 18 - 50 years)
Health Status: healthy
Age Group: 35 years (range: 18 - 50 years)
Sex: M+F
Sources:
60 mg 1 times / day steady, oral
Recommended
unhealthy, 48 years (range: 18-90 years)
Disc. AE: Diarrhea...
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Disc. AE: Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Abdominal pain (0.5%)
Sources:
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.2%)
Sources:
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Disc. AE: Diarrhea, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.7%)
Abdominal pain (0.6%)
Sources:
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Dyspepsia, Eructation...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (3 patients)
Eructation (2 patients)
Nausea (6 patients)
Vomiting (6 patients)
Erosive esophagitis (1 patient)
Sources:
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Disc. AE: Dyspepsia, Eructation...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (1 patient)
Eructation (1 patient)
Nausea (9 patients)
Vomiting (6 patients)
Sources:
60 mg 2 times / day steady, oral
Overdose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
unhealthy
Other AEs: Hypertension...
AEs

AEs

AESignificanceDosePopulation
Diarrhea 0.7%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
unhealthy, 48 years (range: 18-90 years)
Abdominal pain 0.5%
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Diarrhea 0.2%
Disc. AE
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Abdominal pain 0.6%
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Diarrhea 0.7%
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, 48 years (range: 18-90 years)
Health Status: unhealthy
Age Group: 48 years (range: 18-90 years)
Sex: M+F
Sources:
Erosive esophagitis 1 patient
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Eructation 2 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Dyspepsia 3 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Nausea 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Vomiting 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
Dyspepsia 1 patient
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Eructation 1 patient
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Vomiting 6 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Nausea 9 patients
Disc. AE
90 mg 1 times / day steady, oral
Dose: 90 mg, 1 times / day
Route: oral
Route: steady
Dose: 90 mg, 1 times / day
Sources:
unhealthy, adult
Hypertension serious
60 mg 2 times / day steady, oral
Overdose
Dose: 60 mg, 2 times / day
Route: oral
Route: steady
Dose: 60 mg, 2 times / day
Sources:
unhealthy
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
no (co-administration study)
Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered theophylline (CYP1A2 substrate)
Page: 11
unlikely
no (co-administration study)
Comment: in vivo studies showed that DEXILANT did not have an impact on the pharmacokinetics of coadministered phenytoin (CYP2C9 substrate)
Page: 11
weak
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (pharmacogenomic study)
Comment: mean dexlansoprazole Cmax and AUC values were up to 2 times higher in intermediate compared to extensive metabolizers; in poor metabolizers, mean Cmax was up to 4 times higher and mean AUC was up to 12 times higher compared to extensive metabolizers
Page: 10,12
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
2002 Jul
Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.
2004 Nov
Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
2005 Feb
Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
2005 Jan
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
2005 Jul
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.
2005 Jun
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers.
2005 May
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
2006 Dec
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole.
2006 Jan
Enantioselective disposition of lansoprazole and rabeprazole in human plasma.
2006 Jun
Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers.
2008 May
Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.
2009
Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
2009
New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
2009 Dec
Patents

Sample Use Guides

For erosive esophagitis: One 60 mg capsule once daily for up to 8 weeks
Route of Administration: Oral
A stably transfected gene reporter cell line AZ-AHR, derived from human hepatoma HepG2 cells transfected with a construct containing several AhR binding sites upstream of a luciferase reporter gene, was used for assessment of AhR transcriptional activity. Cells were incubated for 24 h with DEXLANSOPRAZOLE and/or vehicle (DMSO; 0.1% v/v), in the presence or absence of TCDD (10 nM; AZ-AHR cells) or DEX (100 nM; AZ-GR cells). After the treatments, cells were lysed and luciferase activity was measured. In parallel, cell viability was determined by conventional MTT test.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:03:43 UTC 2021
Edited
by admin
on Fri Jun 25 21:03:43 UTC 2021
Record UNII
0K5C5T2QPG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LANSOPRAZOLE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
LANSOPRAZOLE [MI]
Common Name English
LANZOR
Brand Name English
AG-1749
Code English
LANSOPRAZOLE [ORANGE BOOK]
Common Name English
2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDYL)METHYL)SULFINYL)BENZIMIDAZOLE
Systematic Name English
LANSOPRAZOLE COMPONENT OF PREVPAC
Common Name English
LANSOPRAZOLE [USP MONOGRAPH]
Common Name English
PREVACID
Brand Name English
PREVPAC COMPONENT LANSOPRAZOLE
Brand Name English
TAKEPRON
Brand Name English
2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
Systematic Name English
A-65006
Code English
LANSOPRAZOLE [EP MONOGRAPH]
Common Name English
LANZOPRAZOLE
Common Name English
AGOPTON
Brand Name English
LANSOPRAZOLE [INN]
Common Name English
(+/-)-LANSOPRAZOLE
Common Name English
PREVONCO
Brand Name English
NSC-758638
Code English
LANSOX
Brand Name English
LANSOPRAZOLE [WHO-DD]
Common Name English
LANSOPRAZOLE [USP-RS]
Common Name English
LIMPIDEX
Brand Name English
LANSOPRAZOLE [HSDB]
Common Name English
LANSOPRAZOLE [JAN]
Common Name English
LANSOPRAZOLE [MART.]
Common Name English
1H-BENZIMIDAZOLE, 2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
OGAST
Brand Name English
ZOTON
Brand Name English
OGASTORO
Brand Name English
LANSOPRAZOLE [VANDF]
Common Name English
LANSOPRAZOLE [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC A02BC03
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-VATC QA02BD07
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
LIVERTOX 541
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-VATC QA02BD03
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-ATC A02BD03
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-VATC QA02BD02
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-ATC A02BD02
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-ATC A02BD10
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-ATC A02BD07
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
NCI_THESAURUS C29723
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-VATC QA02BC03
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
FDA ORPHAN DRUG 446014
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-ATC A02BC53
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
NDF-RT N0000000147
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
NDF-RT N0000175525
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
FDA ORPHAN DRUG 264508
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
WHO-ATC A02BD09
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
Code System Code Type Description
MERCK INDEX
M6683
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY Merck Index
RXCUI
17128
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY RxNorm
NDF-RT
N0000009724
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY Inhibition Gastric Acid Secretion [PE]
PUBCHEM
3883
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
DRUG CENTRAL
1547
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
CAS
103577-45-3
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
INN
6397
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
IUPHAR
7208
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
DRUG BANK
DB00448
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
NCI_THESAURUS
C29150
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
WIKIPEDIA
LANSOPRAZOLE
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
MESH
C058687
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
HSDB
7204
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
LACTMED
Lansoprazole
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
EPA CompTox
103577-45-3
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
USP_CATALOG
1356916
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY USP-RS
FDA UNII
0K5C5T2QPG
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
EVMPD
SUB08403MIG
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
ChEMBL
CHEMBL480
Created by admin on Fri Jun 25 21:03:43 UTC 2021 , Edited by admin on Fri Jun 25 21:03:43 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
DEGRADENT -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INDUCER
ENANTIOMER -> RACEMATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
DEGRADENT -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
METABOLITE ACTIVE -> PRODRUG
METABOLITE -> PARENT
These metabolites have very little or no antisecretory activity.
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC With Hepatic impairment
PHARMACOKINETIC
Elderly
PHARMACOKINETIC